用于治疗精神分裂症的伊潘立酮：最新临床综述。
Iloperidone for the treatment of schizophrenia: an updated clinical review.
作者信息
Weiden Peter J
机构信息
Department of Psychiatry, University of Illinois at Chicago, Chicago, IL 60612-7327, USA.
出版信息
Clin Schizophr Relat Psychoses. 2012 Apr;6(1):34-44. doi: 10.3371/CSRP.6.1.5.
Iloperidone is a second-generation "atypical" antipsychotic whose primary mechanism of action is within the subclass of combined D2/5HT2A antagonism. Iloperidone was approved by the FDA in May 2009 for the treatment of schizophrenia. This review is a comprehensive synthesis of the history and clinical trials data leading up to approval, and evaluates iloperidone within the clinical context of how it compares with other available antipsychotics.
伊潘立酮是一种第二代“非典型”抗精神病药物，其主要作用机制属于D2/5HT2A联合拮抗亚类。伊潘立酮于2009年5月获美国食品药品监督管理局（FDA）批准用于治疗精神分裂症。本综述全面综合了其获批之前的历史和临床试验数据，并在临床背景下评估了伊潘立酮与其他现有抗精神病药物相比的情况。
Zotero 插件